CURRICULUM VITAE DATE UPDATED · CURRICULUM VITAE . DATE UPDATED: August 5, 2013 . PART I: General...

CURRICULUM VITAE

DATE UPDATED: August 5, 2013

PART I: General Information

Name: Merri Lou Pendergrass

Current Position Professor of Medicine Director, Diabetes Program

University of Arizona Office Address: Merri Pendergrass, MD, PhD

Department of Medicine/ Endocrinology 3950 S. Country Club Road Suite C200, Room 2224 Tucson, Arizona 85714

Phone: (520) 626-6334 Fax: (520) 626-7127 Email: [email protected]

Education:

1978 BA (Social Ecology), University of California, Irvine 1985 PhD (Biopsychology), University Of Texas, Austin 1989 MD (Medicine), University Of Texas Southwestern Medical School, Dallas

Postdoctoral Training:

7/89-6/90 Intern in Internal Medicine, University of Texas, San Antonio 7/90-6/92 Resident in Internal Medicine, University of Texas, San Antonio 7/92-6/95 Fellow in Endocrinology and Metabolism, University of Texas, San Antonio

Licensure and Certification:

1989 Federation Licensing Examination 1990-2006 Texas Medical License 1992-2002 Board Certification in Internal Medicine 1995-2005 Board Certification in Endocrinology and Metabolism 1997-2009 Louisiana Medical License 2002-2012 Re-Certification in Internal Medicine 2002-2015 Re-Certification in Endocrinology and Metabolism 2003-2012 Massachusetts Medical License 2008- Texas Medical License 2012- Arizona Medical License

mailto:[email protected]

Merri Pendergrass 11/20/12

Academic Appointments:

1995-1997 Instructor of Medicine, University of Texas Medical School, San Antonio, TX 1997-2001 Assistant Professor of Medicine, Tulane School of Medicine, New Orleans, LA 2001-2003 Associate Professor of Medicine, Tulane School of Medicine, New Orleans, LA 2003-2009 Associate Professor of Medicine, Harvard Medical School, Boston, MA 2009-2012 Assistant Professor of Medicine, University of Texas Medical School, Dallas, TX 2012- Professor of Medicine, University of Arizona

Corporate Positions:

2008-2012 Vice President, Express Scripts (Previously Medco Health Solutions)

Hospital or Affiliated Institution Appointments:

7/95-6/97 Staff Physician, University Hospital/University of Texas Medical School, San Antonio

7/95-6/97 Staff Physician, Audie L. Murphy Veteran's Administration Hospital/University of Texas Medical School, San Antonio

9/97-11/03 Staff Physician, New Orleans Veteran's Administration Medical Center/Tulane School of Medicine, New Orleans, LA

9/97-11/03 Staff Physician, Tulane University Medical Center/Tulane School of Medicine, New Orleans, LA

12/03-1/09 Staff Physician, Brigham and Women's Hospital/Harvard Medical School, Boston, MA

7/05-1/09 Consulting Staff, Dana Farber Cancer Institute/Harvard Medical School, Boston, MA

7/09-8/12 Staff Physician, Parkland Memorial Hospital/University of Texas Southwestern Medical School, Dallas, TX

11/12- Staff Physician, University of Arizona Health Network/University of Arizona, Tucson, AZ

Major Administrative Responsibilities:

1997-2003 Director, Diabetes Program, Medical Center of Louisiana, New Orleans, LA 2003-2008 Director of Clinical Diabetes, Brigham and Women's Hospital,

2004-2008 Interim Chief, Section of Diabetes and Metabolism, Brigham and Women's Hospital, Boston, MA

2006-2008 Associate Clinical Chief, Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, MA

2012- Director of Diabetes Program, University of Arizona College of Medicine

Major Committee Assignments:

Affiliated Institution

1998-2003 Endocrine and Metabolism Subcommittee (P&T) [Chairperson], Medical Center of Louisiana, New Orleans

of 21


1999-2001 Advisory Board, Tulane-Xavier Center for Women's Health, Tulane School of Medicine

1999-2002 Medicine Department Promotions Committee, Tulane School of Medicine

2000-2003 Diabetes Interdisciplinary Committee [Chairperson], Medical Center of Louisiana, New Orleans

2001-2003 Medicine Task Force, Medical Center of Louisiana, New Orleans 2001-2003 Disease Management Committee, Medical Center of Louisiana, New Orleans 2002-2003 University Senate, Tulane School of Medicine 2004-2008 Diabetes Council, Partners Healthcare

2004-2008 Diabetes Subcommittee of Pharmacy and Therapeutics Committee [Chairperson], Brigham and Women's Hospital

2004-2008 Department of Medicine Executive Clinical Council, Brigham and Women's Hospital 2004-2005 Institutional Review Board, Brigham and Women's Hospital 2004-2005 Women's Health Leadership Advisory Group, Brigham and Women's Hospital

2006-2007 Department of Medicine Network Development Group, Brigham and Women's Hospital

Regional 2000-2001 Steering Committee [Chairperson], Louisiana Diabetes Council

2000-2003 Cardiovascular Disease Prevention Steering Committee [Member], Louisiana State Medical Society

2000-2003 Clinical Advisory Committee[Member], Louisiana Health Care Review 2001-2003 Diabetes Advisory Council [Member], Louisiana Department of Health and Hospitals 2013- Board of Directors [Member], American Diabetes Association Tucson Chapter National

2007 Review Committee [Co-chairperson] for AACC Diabetes Guidelines, American College of Physicians

Professional Societies:

1992- American Diabetes Association, Member 1992- American College of Physicians, Fellow 2001- Endocrine Society, Member 2003- American Association of Clinical Endocrinologists, Member

Editorial Boards:

2003- Reviewer, Diabetes Care 2003-2009 Reviewer, New England Journal of Medicine 2003-2004 Reviewer, Drug Benefit Trends 2005-2009 Reviewer, Up-To-Date (www.uptodate.org) 2005-2006 Reviewer, Endocrine Practice 2005-2006 Reviewer, Metabolic Syndrome and Related Disorders 2006- Advisory Board, Nature Reviews Endocrinology

of 21


2005-2009 Editorial Board, Diabetes Care (Editor, Global Literature 2005-2008) 2009- Reviewer, Diabetes Care 2009- Reviewer, Diabetes, Obesity and Metabolism 2009- Reviewer, Journal of Diabetes and Its Complications 2010- Reviewer, Metabolism 2010- Reviewer, Primary Care Diabetes

Part II: Research, Teaching, and Clinical Contributions

Funding Information

1993-1995 P.I., Juvenile Diabetes Foundation, Regulation of Transmembrane Glucose Transport and Intracellular Glucose Phosphorylation in IDDM and NIDDM

1995-1998 P.I., N.I.H., Regulation of Transmembrane Glucose Transport and Intracellular Glucose Phosphorylation in vivo in Humans

2000-2002 P.I., Centers for Disease Control, New Orleans REACH 2010: Diabetes Prevention and Management

2000-2002 Consultant, American Heart Association, Effects Of Estrogen Replacement In Type 2 Diabetes

2001-2002 Investigator, Pfizer, Use of Telemedicine for Early Detection and Treatment of Diabetic Retinopathy

2005-2006 Co-P.I., Novo Nordisk, Improving Glycemic Control on GMS: A Quality Improvement Study

Report of Teaching

1. Local contributions

a. Medical School Courses 1997 Mechanisms of Disease: Pathology and Pathophysiology

contact time prep time Conference Leader 150 Medical Students 2 hours/year

for 1 year(s) 2 hours/year for 1 year(s)

Lecturer 150 Medical Students 1 hours/year for 1 year(s)

8 hours/year for 1 year(s)

1997 Internal Medicine Clerkship: Junior Core Lecture Series

contact time prep time Lecturer 150 Medical Students 6 hours/year


1997 Diabetes Clinic Core Lecture Series



of 21


1998 Mechanisms of Disease: Pathology and Pathophysiology





1998 Pharmacology











1999 Biochemistry








1999 Pharmacology








of 21
















2000 Pharmacology





2000 Biochemistry


for 1 year(s) none reported



2001 Pharmacology





2001 Biochemistry



of 21













2002 Pharmacology
















2002 Biochemistry



2003 Diabetes Clinic Core Lecture Series contact time prep time

of 21


Conference Leader 150 Medical Students 12 hours/year for 1 year(s)


2003 Pharmacology













2003 Biochemistry



2004 HMSII Diabetes Module



b. Graduate Medical Courses 1997 Diabetes Topics

contact time prep time Lecturer 100 Residents 2 hours/year


1998 Diabetes Topics



1999 Diabetes & Endocrinology Topics



of 21














2004 Diabetes Topics



2005 Morning Report

contact time prep time Discussant 60 Residents 3 hours/year

for 1 year(s) none reported










of 21


2008 Diabetes & Endocrinology Topics contact time prep time

Lecturer 200 Residents 15 hours/year for 1 year(s)


c. Local Invited Presentations Grand Rounds

1998 New Approaches to the Treatment of Hyperglycemia in Patients with Type 2 Diabetes

Mellitus (Medicine), Tulane University Lecturer: 200 participants, 1 hour contact time per year, 20 hours prep time per year

1998 Case of Diabetic Ketoacidosis (Medicine), Tulane University Lecturer: 200 participants, 1 hour contact time per year, 20 hours prep time per year

1998 New Approaches to the Treatment of Hyperglycemia in Patients with Type 2 Diabetes

Mellitus (Surgery) , Tulane University Lecturer: 50 participants, 4 hours contact time per year, 4 hours prep time per year

1999 Treatment of Hyperglycemia in Type 2 Diabetes (Medicine), Louisiana State

University Lecturer: 200 participants, 1 hour contact time per year, 8 hours prep time per year

2001 Thyrotoxic Periodic Paralysis (Medicine), Tulane University Lecturer: 200 participants, 16 hours contact time per year, 16 hours prep time per year

2004 Diabetes Care at BWH (Medicine), Brigham and Women's Hospital Lecturer: 150 participants, 1 hour contact time per year, 40 hours prep time per year

2005 Treatment of Hyperglycemia in T2DM (Primary Care), Harvard University Health

System Lecturer: 30 participants, 1 hour contact time per year, 6 hours prep time per year

2006 Metabolic Syndrome (Primary Care), Brigham and Women's Hospital Lecturer: 40 participants, 1 hour contact time per year, 8 hours prep time per year

2007 Inpatient Diabetes Management (OB-GYN), Brigham and Women's Hospital Lecturer: 30 participants, 1 hour contact time per year, 4 hours prep time per year

2008 Treatment of Hyperglycemia in Type 2 Diabetes (Medicine), Compass Healthcare

System Lecturer: 60 participants, 1 hour contact time per year, 4 hours prep time per year

2008 How Do You Measure Diabetes Quality of Care? (Endocrine), University of Texas Southwestern Medical School

of 21


Other

1999 Treatment of Hyperglycemia in Type 2 Diabetes (NP students), Tulane University Lecturer: 20 participants, 1 hour contact time per year, 4 hours prep time per year

2000 Diabetes Clinical Practice Recommendations (PCPs), Tulane University Lecturer: 12 participants, 1 hour contact time per year, 4 hours prep time per year

2000 Treatment of Hyperglycemia in Type 2 Diabetes (PCPs), Tulane University Lecturer: 12 participants, 1 hour contact time per year, 4 hours prep time per year

2000 Diabetes Case Discussions (PCPs), Tulane University Lecturer: 12 participants, 2 hours contact time per year, 2 hours prep time per year

2001 Overview of Diabetes (OT students), Tulane University Lecturer: 20 participants, 1 hour contact time per year, 4 hours prep time per year

2002 Overview of Diabetes (OT students), Tulane University Lecturer: 20 participants, 1 hour contact time per year, 4 hours prep time per year

2004 Inpatient Diabetes (Hospitalists), Society of Hospital Medicine (Boston Chapter) Lecturer: 50 participants, 1 hour contact time per year, 8 hours prep time per year

2004 Diabetes Self-Management Education (Physicians), Partners Healthcare Lecturer: 100 participants, 1 hour contact time per year, 4 hours prep time per year

2005 Exercise and Diabetes (PCPs), Massachusetts General Hospital Lecturer: 15 participants, 1 hour contact time per year, 8 hours prep time per year

2005 Inpatient Diabetes (Nurse Educators), Brigham and Women's Hospital Lecturer: 50 participants, 2 hours contact time per year, 4 hours prep time per year

2005 Overview of Diabetes (PAs), Brigham and Women's Hospital Lecturer: 20 participants, 1 hour contact time per year, 2 hours prep time per year

2006 Inpatient Diabetes Management (Hospitalists), Brigham and Women's Hospital Lecturer: 20 participants, 1 hour contact time per year, 4 hours prep time per year

2006 Inpatient Diabetes (Dietitians), Brigham and Women's Hospital Lecturer: 30 participants, 1 hour contact time per year, 2 hours prep time per year

2006 Diabetes and Heart Disease (Advanced Heart Failure Physicians), Brigham and

Women's Hospital Lecturer: 40 participants, 1 hour contact time per year, 8 hours prep time per year

2006 Inpatient Diabetes (Nurse Educators), Brigham and Women's Hospital Lecturer: 20 participants, 1 hour contact time per year, 4 hours prep time per year

of 21


2006 Overview of Diabetes (PAs), Brigham and Women's Hospital Lecturer: 20 participants, 1 hour contact time per year, 4 hours prep time per year

2007 Inpatient Diabetes (Nurses), Partners Healthcare Lecturer: 100 participants, 1 hour contact time per year, 6 hours prep time per year

2008 Treatment of Hyperglycemia in Type 2 Diabetes (Pharmacists), Massachusetts

Association of Health Systems Pharmacists Lecturer: 100 participants, 1 hour contact time per year, 6 hours prep time per year

Seminar

1998 In Vivo Glucose Transport And Phosphorylation Are Impaired By Increased Free Fatty

Acids, Tulane University Lecturer: 30 participants, 1 hour contact time per year, 16 hours prep time per year

1999 The Hyperinsulinemic Euglycemic Clamp, Tulane University Lecturer: 20 participants, 1 hour contact time per year, 8 hours prep time per year

2000 HKII mRNA and Protein are Reduced in Obesity and Type 2 Diabetes, Tulane

University Lecturer: 20 participants, 1 hour contact time per year, 8 hours prep time per year

Telemedicine

2005 Live Telecast (Physicians in Egypt), Partners Lecturer: 4000 participants, 2 hours contact time per year, 16 hours prep time per year

2005 Live Webcast (Physicians in USA), Partners Lecturer: 1000 participants, 2 hours contact time per year, 20 hours prep time per year

2006 Live Webcast (Physicians in Saudi Arabia), Partners Lecturer: 1000 participants, 2 hours contact time per year, 16 hours prep time per year

2008 Live Webcast (Physicians in Saudi Arabia), Partners Lecturer: 2000 participants, 2 hours contact time per year, 16 hours prep time per year

d. Continuing Medical Education Courses

1998 Tulane Nephrology Update Lecturer: 200 participants, 1 hour contact time per year, 8 hours prep time per year

1998-2003 Tulane/LSU/Ochsner Internal Medicine Board Review Course Lecturer: 600 participants, 1 hour contact time per year, 8 hours prep time per year

1999-2003 New Orleans Endocrine Club

Coordinator : 30 participants, 36 hours contact time per year, 12 hours prep time per year

of 21


1999-2003 Tulane Diabetes Update Lecturer: 100 participants, 1 hour contact time per year, 8 hours prep time per year

2000-2009 Methodist Healthcare: Primary Care Issues in Women's Health (Memphis) Lecturer: 75 participants, 2 hours contact time per year, 16 hours prep time per year

2000-2009 Methodist Healthcare: Medical Review for the Primary Care Physician (Amelia

Island) Lecturer: 75 participants, 2 hours contact time per year, 16 hours prep time per year

2000-2009 Methodist Healthcare: Advances in Medicine (Kona, Maui, Cancun, Grand Cayman,

Sea Island) Lecturer: 75 participants, 2 hours contact time per year, 16 hours prep time per year

2001-2003 Tulane-Xavier Center for Women Health: Contemporary Issues in Women's Health Lecturer: 50 participants, 1 hour contact time per year, 4 hours prep time per year

2002-2003 Tulane Family Practice Update Lecturer: 100 participants, 1 hour contact time per year, 4 hours prep time per year

2004-2008 Brigham and Women's Hospital: Office Practice of Primary Care Medicine Lecturer: 200 participants, 1 hour contact time per year, 8 hours prep time per year

2004-2009 Brigham and Women's Hospital: Intensive Review of Internal Medicine

(Section Leader 2006-2008): 600 participants, 2-3 hours contact time per year, 30 hours prep time per year

2006-2009 PriMed: Current Clinical Issues in Primary Care (Anaheim, Baltimore, Boston,

Chicago, Houston, Ft. Lauderdale) Lecturer: 3000 participants, 6 hours contact time per year, 30 hours prep time per year

2007-2009 Brigham and Women's Hospital: Cardiovascular Medicine: Review and Update for

the Practitioner Lecturer: 200 participants, 1 hour contact time per year, 8 hours prep time per year

2008- American Medical Seminars: Internal Medicine Update (Sarasota, Florida) Lecturer: 100 participants, 4 hour contact time per year,20 hours prep time per year

e. Advisory and Supervisory Responsibilities in Clinical Setting

1997-2003 6 Residents and Medical Students for 140 hrs/year, Attending, Inpatient General Medical Service, Tulane University

1997-2003 100 Fellows, Residents and Medical Students for 600 hrs/year, Supervising in Ambulatory Clinic, Tulane University

1997-2003 30 Fellows, Residents and Medical Students for 180 hrs/year, Attending, Inpatient

of 21


Endocrine Consult Service, Tulane University

2004-2008 5 Fellows, Residents and Medical Students for 40 hrs/year, Attending, Inpatient Endocrine Consult Service, Brigham and Women's Hospital

2004-2008 6 Residents and Medical Students for 50 hrs/year, Attending, Inpatient General Medicine Service, Brigham and Women's Hospital

2004-2008 6 Fellows and Residents for 150 hrs/year, Supervising in ambulatory clinic, Brigham and Women's Hospital

2009-2012 8 Fellows, Residents, and students for 300 hrs/year, Supervising in ambulatory clinic, Parkland Memorial Hospital

2012- 5 Fellows, Residents, and students for 500 hrs/year, Supervising in ambulatory clinic, University of Arizona Medical Center

g. Advisees/Trainees

Training Duration

Name Current Position

2000-2002 Pitiporn Suwattee Assistant Professor, University of Minnesota 2004-2005 Alexander Turchin Assistant Professor, Harvard Medical School

2. Regional, national, or international contributions

a. Invited Presentations Regional 1999 Medicine Grand Rounds, Earl K. Long Medical Center, Baton Rouge, LA[Invited

Lecture]

1999 Annual Meeting, American College of Physicians-American Society for Internal Medicine Louisiana and Mississippi Chapters[Invited Lecture]

2001 Annual Meeting, Louisiana Primary Care Association[Invited Lecture] 2002 Annual Meeting, Louisiana Association of Family Practices[Invited Lecture] 2002 Annual Meeting, New Orleans Society of Internal Medicine[Invited Lecture] 2004 Conference, Society of Hospital Medicine, Boston Chapter[Invited Lecture] 2007 Endocrine Grand Rounds, Baystate Hospital Endocrine Division[Invited Lecture]

of 21


National 1998 Annual Meeting, Alabama Academy of Family Physicians[Invited Lecture] 1999 Medicine Grand Rounds, Southeast Alabama Medical Center, Dothan, AL[Invited

Lecture] 1999 Annual Meeting, Tennessee Academy of Family Physicians[Invited Lecture] 1999 Annual Meeting, Bay County Florida Medical Society[Invited Lecture] 1999 Conference, Atlanta Endocrine Society[Invited Lecture] 2000 Medicine Grand Rounds, Saint Francis Hospital, Memphis, TN[Invited Lecture] 2000 Conference, University of Tennessee, Family Practice Department[Invited Lecture] 2000 Medicine Grand Rounds, University of Alabama, Birmingham, AL[Invited Lecture] 2002 Conference, Fayetteville Diagnostic Clinic, Washington Regional Hospital[Invited

Lecture] International 2002 Conference, Universidad Centroamericana de Nicaragua[Invited Lecture] 2002 Conference, Hospital MOCEL, Mexico D.F.[Invited Lecture] 2008 Conference, Asan Medical Center, Seoul Korea [Visiting Professor]

4. Report of Clinical Activities

1995-1997 Endocrinology, University of Texas, San Antonio

Clinical Activity Description: Outpatient Clinic Patient Load: 700 visits per/yr

1995-1997 General Medicine, University of Texas, San Antonio

Clinical Activity Description: Inpatient General Medical Service Patient Load: 100 visits per/yr

1997-2003 Endocrinology, Tulane University

Clinical Activity Description: Outpatient clinic Patient Load: 2300 visits per/yr

1997-2003 Diabetes, Brigham and Women's Hospital

Clinical Activity Description: Inpatient service Patient Load: 400 visits per/yr

2004-2008 Endocrinology, Brigham and Women's Hospital

Clinical Activity Description: Outpatient Clinic Patient Load: 400 visits per/yr

of 21


2004-2008 General Medicine, Brigham and Women's Hospital


2005-2008 Endocrinology Consult, Brigham and Women's Hospital


2009- Endocrinology/Diabetes Outpatient Service, Parkland Memorial Hospital

Clinical Activity Description: Teaching clinic Patient Load: 300 visits per/yr

Part III: Bibliography

Original Articles

1. Pendergrass ML, Thiessen DD. Body temperature and autogrooming in the Mongolian gerbil, Meriones unguiculatus. Behav Neural Biol. 1981;33(4):524-8.

2. Thiessen D, Harrisman A, Pendergrass M. The thermoenergetics of coat colour maintenance by the Mongolian gerbil, Meriones unguiculatus. Journal of Thermal Biology. 1982;7:51-56.

3. Schallert T, Pendergrass M, Farrar SB. Cholecystokinin-octapeptide effects on eating elicited by "external" versus "internal" cues in rats. Appetite. 1982;3(2):81-90.

4. Thiessen DD, Pendergrass M. Harderian gland involvement in facial lesions in the Mongolian gerbil. J Am Vet Med Assoc. 1982;181(11):1375-7.

5. Pendergrass M, Thiessen D. Sandbathing is thermoregulatory in the Mongolian gerbil, Meriones unguiculatus. Behav Neural Biol. 1983;37(1):125-33.

6. Thiessen D, Pendergrass M, Young RK. The Ddevelopment and expression of autogrooming in the Mongolian gerbil, Meriones unguiculatus. J Comp Psychol. 1983;97(3):187-90.

7. Thiessen D, Pendergrass M. Change of pelage lipids in the Mongolian gerbil, Meriones unguiculatus, as the result of autogrooming and sandliving. Journal of Mammology. 1985;66(3):469-475.

8. Pendergrass M, Thiessen D, Friend P. Ventral marking in the male Mongolian gerbil reflects present and future reproductive investments. Percept Mot Skills. 1989;69(2):355-67.

9. Vogt C, Yki-Jarvinen H, Iozzo P, Pipek R, Pendergrass M, Koval J, Ardehali H, Printz R, Granner D, Defronzo R, Mandarino L. Duel effects of insulin on subcellular localization of hexokinase II in human skeletal muscle in vivo. J Clin Endocrinol Metab. 1998;83(1):230-4.

10. Pendergrass M, Koval J, Vogt C, Yki-Jarvinen H, Iozzo P, Pipek R, Ardehali H, Printz R, Granner D, DeFronzo RA, Mandarino LJ. Insulin-induced hexokinase II expression is reduced in obesity and NIDDM. Diabetes. 1998;47(3):387-94.

11. Pendergrass M, Fazioni E, Collins D, DeFronzo RA. IGF-I increases forearm blood flow without increasing forearm glucose uptake. Am J Physiol. 1998;275(2 Pt 1):E345-50.

12. Koval JA, Maezono K, Patti ME, Pendergrass M, DeFronzo RA, Mandarino LJ. Differential effects of moderate exercise and physiological hyperinsulinemia on phosphorylation and activity of insulin signaling porteins in vivo in human skeletal muscle. Med Sci Sports Exerc. 1999;31(7):998-1004.

of 21


13. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, DeFronzo RA, Kahn CR, Mandarino LJ. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest. 2000;105(3):311-20.

14. Vogt C, Ardehali H, Iozzo P, Yki-Järvinen H, Koval J, Maezono K, Pendergrass M, Printz R, Granner D, DeFronzo R, Mandarino L. Regulation of hexokinase II expression in human skeletal muscle in vivo. Metabolism. 2000;49(6):814-8.

15. Osman AA, Pendergrass M, Koval J, Maezono K, Cusi K, Pratipanawatr T, Mandarino LJ. Regulation of MAP kinase pathway activity in vivo in human skeletal muscle. Am J Physiol Endocrinol Metab. 2000;278(6):E992-9.

16. Suwattee P, Lynch JC, Pendergrass ML. Quality of care for diabetic patients in a large urban public hospital. Diabetes Care. 2003;26(3):563-8.

17. Turchin A, Pendergrass ML, Kohane IS. DITTO - A tool for identification of patient cohorts from the text of physician notes in the electronic medical record. AMIA Annu Symp Proc. 2005: pp. 744-8.

18. Turchin A, Kohane IS, Pendergrass ML. Identification of patients with diabetes from the text of physician notes in the electronic medical record. Diabetes Care. 2005;28(7):1794-5.

19. Jawa A, Nachimuthu S, Pendergrass M, Asnani S, Fonseca V. Impaired vascular reactivity in African-American patients with type 2 diabetes mellitus and microalbuminuria or proteinuria despite angiotensin-converting enzyme inhibitor therapy. J Clin Endocrinol Metab. 2006;91:31-35.

20. Schnipper JL, Barsky EE, Shaykevich S, Fitzmaurice G, Pendergrass ML. Inpatient management of diabetes and hyperglycemia among general medicine patients at a large teaching hospital. J Hosp Med. 2006;1(3):145-50.

21. Turchin A, Kolatkar NS, Grant RW, Makhni EC, Pendergrass ML, Einbinder JS. Using regular expressions to abstract blood pressure and treatment intensification information from the text of physician notes. J Am Med Inform Assoc. 2006;13(6):691-5.

22. Turchin A, Kolatkar NS, Grant RW, Makhni EC, Pendergrass ML, Einbinder JS. Computational analysis of non-adherence and non-attendance using the text of narrative physician notes in the electronic medical record. Medical Informatics and Internet in Medicine. 2007;32(2):93-102.

23. Pendergrass ML, Cobelli C, Bonadonna R, Mandarino L, DeFronzo RA. Muscle glucose transport and phosphorylation in type 2 diabetic, obese non-diabetic and genetically predisposed individuals. American Journal of Physiology: Endocrinology and Metabolism. 2007;292:E92-E100.

24. Garg R, Bhutani H, Jarry A, Pendergrass ML. Provider response to insulin induced hypoglycemia in hospitalized patients. J Hosp Med. 2007;2(4):258-60.

25. Turchin A, Shubina M, Pendergrass ML. Relationship of physician volume to process measures and outcomes in diabetes. Diabetes Care. 2007;30(6):1442-7.

26. Garg R, Bhutani H, Alyea E, Pendergrass M. Hyperglycemia and length of stay in patients hospitalized for bone marrow transplantation. Diabetes Care. 2007;30(4):993-4.

27. Turchin A, Shubina M, Chodos AH, Einbinder JS, Pendergrass ML. Effect of board certification on anti-hypertensive treatment intensification in patients with diabetes. Circulation. 2008;117(5):623-8.

28. Trujillo JM, Barsky EE, Greenwood BC, Wahlstrom SA, Shaykevich S, Pendergrass ML,

of 21


Schnipper JL. Improving glycemic control in medical inpatients: a pilot study. J Hosp Med. 2008;3(1):55-63.

29. Matheny ME, Shubina M, Kimmel ZM, Pendergrass ML, Turchin A. Treatment intensification and blood glucose control among hospitalized diabetic patients. J Gen Intern Med. 2008;23(2):184-9.

30. Jawa A, Nachimuthu S, Pendergrass M, Asnani S, Fonseca V. Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension. J Diabetes Complications. 2008 Sep-Oct;22(5):303-8.

31. Turchin A, Wheeler HI, Labreche M, Chu JT, Pendergrass ML, Einbinder JS. Identification of documented medication non-adherence in physician notes. AMIA Annu Symp Proc. 2008 Nov 6:732-6.

32. Schnipper JL, Ndumele CD, Liang CL, Pendergrass ML. Effects of a subcutaneous insulin protocol, clinical education, and computerized order set on the quality of inpatient management of hyperglycemia: results of a clinical trial. J Hosp Med. 2009 Jan;4(1):16-27.

33. Turchin A, Shubina M, Breydo E, Pendergrass ML, Einbinder JS. Comparison of Information. Content of Structured and Narrative Text Data Sources on the Example of Medication Intensification. J Am Med Inform Assoc. 2009 May-Jun;16(3):362-70. Epub 2009 Mar 4.

34. Turchin A, Matheny M, Shubina M, Scanlon J, Greenwood B, Pendergrass, M. Hypoglycemia and Clinical Outcomes in Patients with Diabetes Hospitalized on the General Ward. Diabetes Care July 2009 32:1153-1157

35. Garg RK, Jarry A, Pendergrass M. Delay in Blood Glucose Monitoring During an Insulin Infusion Protocol is Associated with Increased Risk of Hypoglycemia in Intensive Care Units. J Hosp Med. 2009 Jul;4(6):E5-7

36. Cyrus RM, Szumita PM, Greenwood BC, Pendergrass ML. Evaluation of compliance with a paper-based, multiplication-factor, intravenous insulin protocol. Ann Pharmacother. 2009 Sep;43(9):1413-8.

37. Schnipper JL, Liang CL, Ndumele CD, Pendergrass ML. Effects of a Computerized Order Set on the Inpatient Management of Hyperglycemia: A Cluster-Randomized Controlled Trial. Endocr Pract. 2009 Nov 26:1-30.

38. Aubert RE, Herrera V, Chen W, Haffner SM, Pendergrass, M. Rosiglitazone and Pioglitazone Increase Fracture Risk in Women and Men with Type 2 Diabetes. Diabetes, Obesity and Metabolism. Diabetes Obes Metab. 2010 Aug;12(8):716-21

39. Garg R, Chen W, Pendergrass M. Acute Pancreatitis in Type 2 Diabetes Treated with Exenatide or Sitagliptin: A Retrospective Observational Pharmacy Claims Analysis. Diabetes Care 33:2349–2354, 2010.

40. Aggarwal A, Rawn JD, Pendergrass M, Garg K. Subcutaneous insulin after cardiac surgery. Endocrine Practice 17(4):558-562, 2011.

41. Chen W, Fenton C, Haffner SM, Pendergrass, M. Acute Renal Failure in Type 2 Diabetes Treated with Exenatide or Sitagliptin: A Retrospective Observational Pharmacy Claims Analysis. Diabetes Obes Metab. 2012 Jul;14(7):596-600.

42. Pittman D, Fenton C, Haffner SM, Pendergrass, M. Relation of Statin Nonadherence and Treatment Intensification. Am J Cardiol. 2012 Nov 15;110(10):1459-63. doi: 10.1016/j.amjcard.2012.07.008. Epub 2012 Aug 8.

of 21

http://www.ncbi.nlm.nih.gov/pubmed/18998827?ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

http://www.ncbi.nlm.nih.gov/pubmed/18998827?ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum


Reviews/Chapters/Editorials

1. Pendergrass M, Fazioni E, DeFronzo RA. Overview: Type II Diabetes and Gestational Diabetes, Same Disease Another Name? Diabetes Reviews. 1995;3(4):566-583.

2. Pendergrass M, Greybill J. Infections in Diabetes Mellitus. In: Current Therapy of Diabetes Mellitus; DeFronzo RA (editor). New York: Mosby;1998. p. 218-224.

3. Pendergrass ML. Pathophysiology and Management of Type 2 Diabetes. In: Diabetes and Cardiovascular Disease-A Practical Primer T Giles, M Weber, J Sowers (editors). New Orleans, LA: Louisiana State University Publications;2000. p. 15-40.

4. Parulker A, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Non-hypoglycemic Effects of Thiazolidinediones. Annals of Internal Medicine. 2001;134(1):61-71.

5. Pendergrass M, Johnson J. Pathophysiology and Management of Type 2 Diabetes. Cardiovascular Reviews and Reports. 2001;22(11):665-673.

6. DeSouza C, Pendergrass M, Fonseca V. The Insulin Resistance Syndrome (Syndrome X) - Including Vascular Abnormalities. Textbook of Type 2 Diabetes Goldstein and Müller-Wieland (editors). 2004.

7. Pendergrass M. Can Inhaled Insulin Improve Glycemic Control of Type 2 Diabetes? Practice Point Nature Clinical Practice, Endocrinology and Metabolism. 2006;2(5):1-2.

8. Szmuilowicz ED, Pendergrass M. Diabetes and The Metabolic Syndrome. In: Critical Pathways in Cardiovascular Medicine Cannon and O'Gara (editors). Lippincott, Williams and Wilkins;2006. p. 249-259.

9. Green D, Mandarino L, and Pendergrass M. Exercise in Diabetes. In: Clinical Diabetes- Translating Research Into Practice. Fonseca V (editor). Elsevier Publishers;2006. p. 921-931.

10. Garg RA and Pendergrass M. Is Hyperglycemia Important in Acute Stroke? Practice Point. Nature Clinical Practice, Endocrinology and Metabolism, 2006;2(10):544-5.

11. Pendergrass M. Diabetes: A Special Issue. Nature Clinical Practice, Endocrinology and Metabolism. 2007;3(1):1.

12. Greenwood B, Szumita PM, Pendergrass M. Conversion to insulin devices in the inpatient setting. Am J Health Syst Pharm. 2008 Apr 15;65(8):698-9.

13. Bentley-Lewis R, Pendergrass ML. Exercise Prescription for Metabolic Syndrome in: Therapeutic Strategies for the Metabolic Syndrome. Fonseca V (editor). Clinical Publishing; 2008. p. 29-41.

14. Fonseca V, Pendergrass M, McDuffy R. Handbook of Diabetes. Current Medicine Group (Springer); 2008.

15. Saxena A, Pendergrass ML. Treatment of diabetes in non-critically ill patients. In: Just the Facts Hospital Medicine; McKean S (editor). McGraw-Hill; 2008.

16. Pendergrass M. Does intensive glycemic control improve cardiovascular outcomes? Nat Clin Pract Endocrinol Metab. 2008 Oct;4(10):529.

17. Yang J, Singh AK, Magee CC, Pendergrass ML, Ahmed SB. A Potential Living Kidney Donor with Prediabetes. Kidney International. 2009 Sep; 76(6):673-7.

18. Fonseca V, Pendergrass M, McDuffy R. Diabetes in Clinical Practice. Current Medicine Group (Springer Science); 2010.

of 21


Clinical Communications

1. Pendergrass M, Lynch C. Clinical Application of the American Diabetes Assoication Clinical Practice Guidelines. Newsletter for Louisiana Medicaid Providers. Louisiana Medicaid Pharmacy Benefit Management Program. 2000;Fall.

2. Pendergrass M. Prevention of Diabetic Complications. Quality Times Louisiana Health Care Review. 2000;4(6):3-4.

3. Pendergrass M. Screening for Type 2 Diabetes. Quality Times Louisiana Health Care Review. 2000;4(5):3-4.

4. Pendergrass M. Understanding Diabetes. Quality Times. Louisiana Health Care Review. 2000;4(4):2-3.

5. Lynch C, Pendergrass M. Treatment of Hyperglycemia. Quality Times Louisiana Health Care Review. 2001;5(1):2-3.

6. Pendergrass M, Lynch C. American Diabetes Association Clinical Practice Guidelines: Information for Patients. Brochure for Louisiana Medicaid Recipients. Louisiana Medicaid Pharmacy Benefit Management Program. 2002;Fall.

7. Lynch C, Pendergrass M. Exercise and Diabetes: A Guide of Patients. Brochure for Louisiana Medicaid Recipients. Louisiana Medicaid Pharmacy Benefit Management Program. 2003;Summer.

8. Szumita PM, Greenwood B, Anger K, Pendergrass M. Prevention and Treatment of Hyperglycemia in Hospitalized Patients. Pharmacy Times. 2007.

9. Pendergrass ML. Rosiglitazone Controversy. Journal Watch. 2007;December.

Abstracts (includes only those not published as full manuscripts)

1. Gulli G, Pendergrass M, Consoli A DeFronzo RA. Mechanism of insulin resistance during short term fasting: How short is short? Diabetes 1993;43(Suppl 1):14A.

2. Gulli G Pendergrass M. Time of day, rather than length of fast, accounts for insulin resistance in the afternoon. Diabetes 1994;43 (Suppl 1):55A.

3. Pendergrass M, Nucci G, DeFronzo RA. In vivo glucose transport (GT) and phosphorylation (GP) in skeletal muscle are impaired by elevation of plasma FFA. Diabetes 1998;47 (Suppl 1):A64..

4. Turchin A, Einbinder JS, Pendergrass ML. CLINDOC - A software tool for detection of clinical inertia in management of blood pressure in patients with diabetes mellitus through analysis of free text physician notes. Fifth Annual Diabetes Technology Meeting. 2005.

5. Garg R, Egorova S, Pendergrass M, Blacker D, Hoffman K, Killiany RJ, Guttmann CRG. Brain parenchymal fraction and white matter signal abnormalities in patients with type 2 diabetes mellitus subjects are similar to non-diabetic subjects. Endocrine Society National Meeting. 2006.

6. Turchin A, Grant RW, Einbinder JS, Pendergrass ML. Clinical inertia in management of hypertension in diabetic patients. Diabetes 2006;55 (Suppl 1):A.

7. Vimalananda V, Pendergrass M, Garg R. Transition from intravenous to subcutaneous insulin in stress hyperglycemia. Annual Meeting of the American Association of Clinical Endocrinologists, Seattle, WA. 2007.

of 21


8. Manwani B, LeBoff MS, Pendergrass M, Garg R. Lack of Correlation between Glycemic Control and Bone Mineral Density in Type 2 Diabetic Women. To be presented at the Annual Meeting of the American Society for Bone and Mineral Research (ASBMR), Montréal, Québec, Canada, 2008

9. Konkus R, Utterdyke J, Peppers S, Moore J, Bhandari I, Dasmahapatra A, Pendergrass M. A pharmacy-driven physician fax program increases use of ACE/ARBs in diabetic patients. Diabetes 2009; (Suppl 1)

of 21

CURRICULUM VITAE DATE UPDATED · CURRICULUM VITAE . DATE UPDATED: August 5, 2013 . PART I: General...

Documents

Transcript of CURRICULUM VITAE DATE UPDATED · CURRICULUM VITAE . DATE UPDATED: August 5, 2013 . PART I: General...